Latigo Biotherapeutics, Inc. (LTGO) shareholders
Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%
Ownership
Who owns Latigo Biotherapeutics's shares
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Dr. Beth C. Seidenberg Joint filing with Westlake BioPartners Fund I, L.P. (9.00%), Westlake BioPartners GP I, LLC (9.00%) and 2 more | 13,199,669 | 19.90% | 13G (passive) | Sep 30, 2026 |
| James B. Tananbaum Joint filing with Foresite Capital Fund V, L.P. (5.60%), Foresite Capital Management V, LLC (5.60%) and 2 more | 9,181,328 | 14.50% | 13D (active) | Aug 10, 2026 |
| RA Capital Healthcare Fund, L.P. Joint filing with RA Capital Management, L.P. (8.40%), Peter Kolchinsky (8.40%) and 1 more | 5,295,690 | 8.40% | 13G (passive) | Aug 10, 2026 |
| Deep Track Capital, LP Joint filing with Deep Track Biotechnology Master Fund, Ltd. (7.03%), David Kroin (7.03%) | 4,446,656 | 7.03% | 13G (passive) | Aug 7, 2026 |
| AI Biotechnology LLC Joint filing with Access Industries Holdings LLC (5.00%), Access Industries Management, LLC (5.00%) and 1 more | 3,185,177 | 5.00% | 13G (passive) | Aug 11, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Nima Farzan | President and CEO, Director | 114,453 | 0.17% | Aug 6, 2026 |
| Neha Krishnamohan | CFO and Chief Business Officer | – | – | Aug 6, 2026 |
| Neil Singla | Chief Medical Officer | – | – | Aug 6, 2026 |
| Todd N. Smith | Director | – | – | Aug 10, 2026 |
| Beth C. Seidenberg | Director, 10% owner | 4,916,374 | 7.42% | Aug 10, 2026 |
| James B. Tananbaum | Director, 10% owner | 3,117,664 | 4.70% | Aug 10, 2026 |
| Timothy P. Walbert | Director | – | – | Aug 6, 2026 |
| Sara Bonstein | Director | – | – | Aug 6, 2026 |
| Kevin Raidy | Director | – | – | Aug 6, 2026 |
| 5AM Opportunities II (GP), LLC | 10% owner | – | – | Aug 12, 2026 |
| 5AM Opportunities II, L.P. | 10% owner | – | – | Aug 12, 2026 |
| Sanofi | 10% owner | 672,788 | 1.01% | Aug 12, 2026 |
| Andrew J. Schwab | 10% owner | – | – | Aug 12, 2026 |
| Kush Parmar | 10% owner | – | – | Aug 12, 2026 |
| 5AM Partners VI, LLC | 10% owner | 7,325,962 | 11.05% | Aug 12, 2026 |
| 5AM Ventures VI, L.P. | 10% owner | – | – | Aug 12, 2026 |
| Westlake BioPartners GP II, LLC | 10% owner | 27,956 | 0.04% | Aug 11, 2026 |
| Westlake BioPartners Opportunity Fund I, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Opportunity GP I, LLC | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Fund II, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners Fund I, L.P. | 10% owner | – | – | Aug 11, 2026 |
| Westlake BioPartners GP I, LLC | 10% owner | 4,995,328 | 7.53% | Aug 11, 2026 |
| Capital Fund VI LP Foresite | 10% owner | 3,414,544 | 5.15% | Aug 10, 2026 |
| Foresite Capital Fund V, L.P. | 10% owner | – | – | Aug 10, 2026 |
| Capital Management VI LLC Foresite | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Management V, LLC | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Opportunity Management V, LLC | 10% owner | – | – | Aug 10, 2026 |
| Foresite Capital Opportunity Fund V, L.P. | 10% owner | – | – | Aug 10, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| 5AM Partners VI, LLC 10% owner | Aug 10, 2026 | Conversion | +4,975,543 | – | – | 4,975,543 |
| 5AM Partners VI, LLC 10% owner | Aug 10, 2026 | Conversion | +2,350,419 | – | – | 2,350,419 |
| Sanofi 10% owner | Aug 10, 2026 | Conversion | +177,978 | – | – | 672,788 |
| Sanofi 10% owner | Aug 10, 2026 | Conversion | +494,800 | – | – | 494,800 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +1,484,401 | – | – | 4,995,328 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +3,464,072 | – | – | 3,510,927 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +1,027,635 | – | – | 5,944,009 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +165,519 | – | – | 5,160,847 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +2,066,857 | – | – | 2,094,813 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +3,547,842 | – | – | 4,916,374 |
| Westlake BioPartners GP I, LLC 10% owner | Aug 10, 2026 | Conversion | +938,979 | – | – | 1,368,532 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +3,547,842 | – | – | 4,916,374 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +938,979 | – | – | 1,368,532 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +1,027,635 | – | – | 5,944,009 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +3,464,072 | – | – | 3,510,927 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +1,484,401 | – | – | 4,995,328 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +165,519 | – | – | 5,160,847 |
| Beth C. Seidenberg Director, 10% owner | Aug 10, 2026 | Conversion | +2,066,857 | – | – | 2,094,813 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +296,880 | – | – | 3,414,544 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +445,320 | – | – | 3,562,984 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +1,125,823 | – | – | 1,125,823 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +742,201 | – | – | 1,868,024 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Buy | +140,000 | $18.00 | $2.52M | 2,008,024 |
| Capital Fund VI LP Foresite 10% owner | Aug 10, 2026 | Conversion | +195,776 | – | – | 2,203,800 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +445,320 | – | – | 3,562,984 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +296,880 | – | – | 3,414,544 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +1,125,823 | – | – | 1,125,823 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +742,201 | – | – | 1,868,024 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Buy | +140,000 | $18.00 | $2.52M | 2,008,024 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +195,776 | – | – | 2,203,800 |
| James B. Tananbaum Director, 10% owner | Aug 10, 2026 | Conversion | +3,117,664 | – | – | 3,117,664 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 3 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Latigo Biotherapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 15,626 shares on Sep 21, 2026 over the last 90 days.
See a number that looks wrong?